>>He said the value of the drug has gone up as other experimental cholesterol drugs have failed or faced setbacks in the past year, including the surprise failure late last year of Pfizer Inc's (PFE.N: Quote, Profile, Research) torcetrapib to raise good cholesterol.
Isis announced several months ago it was launching a year-long auction to find a partner for mipomersen, the most important of its experimental drugs that use antisense technology.
"The NPV's that are coming back from the large companies that are looking at the drug are in the range where our market analyses and our views of the drug are," Crooke said.
"All of them are in the ballpark that we had hoped for," the CEO said.
He said peak annual U.S. sales of the drug, only in high-risk patients, could surpass $2 billion.
"Assume there are 16 million (U.S.) patients who know that if they don't get their LDL (bad cholesterol) down they will have a heart attack in the next five years, that's a fairly motivated group of patients," he added.<<
Sour, I'm afraid that you will unknowingly mislead investors. Ya see, you have a successful record versus the hucksters. :>) Zack and I are doing great observing the huge ocean waves. :>) Have it happy!
Ah, yes. I see my mistake now. I should've been using continuous compounding rather than annual, right?
So that reduces the interest rate to 9.8%.
So, once again, can I ask you to tell me where to go for bank CDs that pay 9.8%, compounded continuously?
$10.50 x (1 + i)^16 = $10.50 + $40.00
Solve for i, the interest rate.
I get 10.967%, Andy. What do you get?
Seems like this is another one of those circumstances where you made the mistake of stating a testable fact. Stick to innuendo. You're much better at that.
I am down some, but not a lot. And considering I also cashed out one short term trade on isis, I'm close to even with todays move up.
I'm only laughing at a bozo who cuts down a uptreding stock while holding another POS downtrending one.